Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Cash & Equivalents for 10 consecutive years, with $175.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 42.92% year-over-year to $175.7 million; the trailing twelve-month figure through Jun 2026 stood at $175.7 million (down 42.92% YoY), and the FY2025 full-year result was $165.6 million, down 9.8% from the prior year.
• Cash & Equivalents retreated to $175.7 million in Q2 2026 per KNSA's latest filing, from $190.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $352.1 million in Q3 2025 and bottomed at $108.0 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $199.3 million across 5 years, with a median of $188.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 44.86% in 2022, then surged 70.05% in 2024.
• Over 5 years, Cash & Equivalents stood at $122.7 million in 2022, then dropped by 12.03% to $108.0 million in 2023, then jumped by 70.05% to $183.6 million in 2024, then decreased by 9.8% to $165.6 million in 2025, then advanced by 6.09% to $175.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $175.7 million, $190.0 million, and $165.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.